401 Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Moyamoya Disease

View at publisher Summarise with VIRAT
Authors: Joanna Mary Roy, Basel Musmar, Ramsay Hafer, Eleni Papadopoulos, Rithvik Kata, Shray Alpesh Patel, Spyridon K. Karadimas, Sravanthi Koduri, Stavropoula I. Tjoumakaris, M. Reid Gooch, Robert H. Rosenwasser, Pascal Jabbour
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease that is commonly associated with comorbidities like type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (GLP-1) receptor agonists are antihyperglycemic agents that have demonstrated the ability to reduce stroke. METHODS: T2DM patients with MMD were retrospectively identified from the TriNetX Research Network. Propensity-score matching was used to create two cohorts based on history of GLP-1 receptor agonist prescription. Kaplan Meier survival curves were used to analyze outcomes of interest- stroke, intracerebral hemorrhage (ICH) and mortality. RESULTS: Of 2,898 MMD patients with T2DM, 573 (19.7%) had a history of GLP-1 receptor agonist prescription and 2,325 (80.3%) did not have a history of GLP-1 receptor agonist prescription. PSM resulted in 322 patients in each group. Patients with MMD and T2DM who received GLP-1 receptor agonists had 32% lower risk of stroke (HR: 0.68, 95% CI: 0.55-0.83, P < 0.001), 65% lower risk of ICH (HR: 0.35, 95% CI: 0.17-0.70, P < 0.01) and 68% lower risk of mortality (HR: 0.32, 95% CI: 0.16-0.62, P < 0.001) compared to MMD patients with T2DM who did not receive GLP-1 receptor agonists. CONCLUSIONS: In this study, MMD patients with T2DM prescribed a GLP-1 receptor agonist had lower risk of stroke, ICH and mortality. Prospective studies and RCTs are needed to clarify their role in MMD management.

Fields of Study & Subjects

Moyamoya disease diagnosis and treatment Diabetes Treatment and Management Diabetes Management and Research

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
112–112
Publication date
26 March 2026
Language
EN